Compare THG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THG | IMVT |
|---|---|---|
| Founded | 1852 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.3B |
| IPO Year | 1995 | N/A |
| Metric | THG | IMVT |
|---|---|---|
| Price | $170.44 | $26.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $196.67 | $29.13 |
| AVG Volume (30 Days) | 315.0K | ★ 1.7M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 73.14 | N/A |
| EPS | ★ 17.31 | N/A |
| Revenue | ★ $6,506,900,000.00 | N/A |
| Revenue This Year | $4.23 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $9.87 | ★ N/A |
| Revenue Growth | ★ 5.26 | N/A |
| 52 Week Low | $147.76 | $12.72 |
| 52 Week High | $188.18 | $27.80 |
| Indicator | THG | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 53.73 |
| Support Level | $166.54 | $25.18 |
| Resistance Level | $181.04 | $27.37 |
| Average True Range (ATR) | 3.90 | 1.16 |
| MACD | -1.46 | -0.08 |
| Stochastic Oscillator | 18.35 | 47.58 |
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.